Substance use and schizophrenia: Adverse correlates in the CATIE study sample

Karin E. Kerfoot, Robert A. Rosenheck, Ismene L. Petrakis, Marvin S. Swartz, Richard S.E. Keefe, Joseph P. McEvoy, T. Scott Stroup, L. Adler, M. Bari, I. Belz, R. Bland, T. Blocher, B. Bolyard, A. Buffenstein, J. Burruss, M. Byerly, J. Canive, S. Caroff, C. Casat, E. Chavez-RiceJ. Csernansky, P. Delgado, R. Douyon, C. D'Souza, I. Glick, D. Goff, S. Gratz, G. T. Grossberg, M. Hale, M. Hamner, R. Jaffe, D. Jeste, S. Diego, A. Kablinger, A. Khan, S. Lamberti, M. T. Levy, J. Lieberman, G. Maguire, T. Manschreck, M. McGee, H. Meltzer, A. Miller, D. Miller, H. Nasrallah, Charles Nemeroff, S. Olson, G. F. Oxenkrug, J. Patel, F. Reimherr, S. Riggio, S. Risch, B. Saltz, G. Simpson, M. Smith, R. Sommi, R. M. Steinbook, M. Stevens, A. Tapp, R. Torres, P. Weiden

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Objective: This study examined the relationship between severity of illicit substance use at the time of study entry in a sample of patients diagnosed with schizophrenia and 18-month longitudinal outcomes, including psychopathology, depression, neurocognition, and quality of life. Methods: Subjects in the Clinical Antipsychotic Trials of Intervention Effectiveness (N = 1432) were divided into three groups according to baseline data: (1) those with moderate/severe drug use, (2) those with mild drug use, and (3) non-users of illicit substances. The groups were compared on other baseline characteristics. Mixed model analysis was used to compare outcomes between the groups using all available outcome data over 18. months, controlling for potential confounding baseline characteristics. Least square means were compared between pairs of groups in the mixed models. Results: Significantly poorer outcomes were observed in the domains of psychosis, symptoms of depression, and quality of life for moderate/severe drug users in comparison with both mild users and abstainers. No significant differences were found on neurocognitive functioning or days of employment. Conclusions: This study suggests that drug use-related impairment co-morbid with schizophrenia may not be a function of use per se but rather, of the severity of use. It highlights the importance of comprehensive assessment and treatment of illicit substance abuse in schizophrenia. Long-term treatment approaches that integrate harm reduction strategies may offer promise in maximizing positive outcomes for such dually diagnosed patients.

Original languageEnglish (US)
Pages (from-to)177-182
Number of pages6
JournalSchizophrenia Research
Volume132
Issue number2-3
DOIs
StatePublished - Nov 1 2011
Externally publishedYes

Fingerprint

Schizophrenia
Quality of Life
Pharmaceutical Preparations
Depression
Harm Reduction
Time and Motion Studies
Drug Users
Least-Squares Analysis
Psychopathology
Psychotic Disorders
Antipsychotic Agents
Substance-Related Disorders
Clinical Trials
Therapeutics

Keywords

  • Concurrent
  • Dual diagnosis
  • Outcomes
  • Schizophrenia
  • Substance abuse

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Kerfoot, K. E., Rosenheck, R. A., Petrakis, I. L., Swartz, M. S., Keefe, R. S. E., McEvoy, J. P., ... Weiden, P. (2011). Substance use and schizophrenia: Adverse correlates in the CATIE study sample. Schizophrenia Research, 132(2-3), 177-182. https://doi.org/10.1016/j.schres.2011.07.032

Substance use and schizophrenia : Adverse correlates in the CATIE study sample. / Kerfoot, Karin E.; Rosenheck, Robert A.; Petrakis, Ismene L.; Swartz, Marvin S.; Keefe, Richard S.E.; McEvoy, Joseph P.; Stroup, T. Scott; Adler, L.; Bari, M.; Belz, I.; Bland, R.; Blocher, T.; Bolyard, B.; Buffenstein, A.; Burruss, J.; Byerly, M.; Canive, J.; Caroff, S.; Casat, C.; Chavez-Rice, E.; Csernansky, J.; Delgado, P.; Douyon, R.; D'Souza, C.; Glick, I.; Goff, D.; Gratz, S.; Grossberg, G. T.; Hale, M.; Hamner, M.; Jaffe, R.; Jeste, D.; Diego, S.; Kablinger, A.; Khan, A.; Lamberti, S.; Levy, M. T.; Lieberman, J.; Maguire, G.; Manschreck, T.; McGee, M.; Meltzer, H.; Miller, A.; Miller, D.; Nasrallah, H.; Nemeroff, Charles; Olson, S.; Oxenkrug, G. F.; Patel, J.; Reimherr, F.; Riggio, S.; Risch, S.; Saltz, B.; Simpson, G.; Smith, M.; Sommi, R.; Steinbook, R. M.; Stevens, M.; Tapp, A.; Torres, R.; Weiden, P.

In: Schizophrenia Research, Vol. 132, No. 2-3, 01.11.2011, p. 177-182.

Research output: Contribution to journalArticle

Kerfoot, KE, Rosenheck, RA, Petrakis, IL, Swartz, MS, Keefe, RSE, McEvoy, JP, Stroup, TS, Adler, L, Bari, M, Belz, I, Bland, R, Blocher, T, Bolyard, B, Buffenstein, A, Burruss, J, Byerly, M, Canive, J, Caroff, S, Casat, C, Chavez-Rice, E, Csernansky, J, Delgado, P, Douyon, R, D'Souza, C, Glick, I, Goff, D, Gratz, S, Grossberg, GT, Hale, M, Hamner, M, Jaffe, R, Jeste, D, Diego, S, Kablinger, A, Khan, A, Lamberti, S, Levy, MT, Lieberman, J, Maguire, G, Manschreck, T, McGee, M, Meltzer, H, Miller, A, Miller, D, Nasrallah, H, Nemeroff, C, Olson, S, Oxenkrug, GF, Patel, J, Reimherr, F, Riggio, S, Risch, S, Saltz, B, Simpson, G, Smith, M, Sommi, R, Steinbook, RM, Stevens, M, Tapp, A, Torres, R & Weiden, P 2011, 'Substance use and schizophrenia: Adverse correlates in the CATIE study sample', Schizophrenia Research, vol. 132, no. 2-3, pp. 177-182. https://doi.org/10.1016/j.schres.2011.07.032
Kerfoot KE, Rosenheck RA, Petrakis IL, Swartz MS, Keefe RSE, McEvoy JP et al. Substance use and schizophrenia: Adverse correlates in the CATIE study sample. Schizophrenia Research. 2011 Nov 1;132(2-3):177-182. https://doi.org/10.1016/j.schres.2011.07.032
Kerfoot, Karin E. ; Rosenheck, Robert A. ; Petrakis, Ismene L. ; Swartz, Marvin S. ; Keefe, Richard S.E. ; McEvoy, Joseph P. ; Stroup, T. Scott ; Adler, L. ; Bari, M. ; Belz, I. ; Bland, R. ; Blocher, T. ; Bolyard, B. ; Buffenstein, A. ; Burruss, J. ; Byerly, M. ; Canive, J. ; Caroff, S. ; Casat, C. ; Chavez-Rice, E. ; Csernansky, J. ; Delgado, P. ; Douyon, R. ; D'Souza, C. ; Glick, I. ; Goff, D. ; Gratz, S. ; Grossberg, G. T. ; Hale, M. ; Hamner, M. ; Jaffe, R. ; Jeste, D. ; Diego, S. ; Kablinger, A. ; Khan, A. ; Lamberti, S. ; Levy, M. T. ; Lieberman, J. ; Maguire, G. ; Manschreck, T. ; McGee, M. ; Meltzer, H. ; Miller, A. ; Miller, D. ; Nasrallah, H. ; Nemeroff, Charles ; Olson, S. ; Oxenkrug, G. F. ; Patel, J. ; Reimherr, F. ; Riggio, S. ; Risch, S. ; Saltz, B. ; Simpson, G. ; Smith, M. ; Sommi, R. ; Steinbook, R. M. ; Stevens, M. ; Tapp, A. ; Torres, R. ; Weiden, P. / Substance use and schizophrenia : Adverse correlates in the CATIE study sample. In: Schizophrenia Research. 2011 ; Vol. 132, No. 2-3. pp. 177-182.
@article{0d48aa9532f24ce3b69c5d22384576d8,
title = "Substance use and schizophrenia: Adverse correlates in the CATIE study sample",
abstract = "Objective: This study examined the relationship between severity of illicit substance use at the time of study entry in a sample of patients diagnosed with schizophrenia and 18-month longitudinal outcomes, including psychopathology, depression, neurocognition, and quality of life. Methods: Subjects in the Clinical Antipsychotic Trials of Intervention Effectiveness (N = 1432) were divided into three groups according to baseline data: (1) those with moderate/severe drug use, (2) those with mild drug use, and (3) non-users of illicit substances. The groups were compared on other baseline characteristics. Mixed model analysis was used to compare outcomes between the groups using all available outcome data over 18. months, controlling for potential confounding baseline characteristics. Least square means were compared between pairs of groups in the mixed models. Results: Significantly poorer outcomes were observed in the domains of psychosis, symptoms of depression, and quality of life for moderate/severe drug users in comparison with both mild users and abstainers. No significant differences were found on neurocognitive functioning or days of employment. Conclusions: This study suggests that drug use-related impairment co-morbid with schizophrenia may not be a function of use per se but rather, of the severity of use. It highlights the importance of comprehensive assessment and treatment of illicit substance abuse in schizophrenia. Long-term treatment approaches that integrate harm reduction strategies may offer promise in maximizing positive outcomes for such dually diagnosed patients.",
keywords = "Concurrent, Dual diagnosis, Outcomes, Schizophrenia, Substance abuse",
author = "Kerfoot, {Karin E.} and Rosenheck, {Robert A.} and Petrakis, {Ismene L.} and Swartz, {Marvin S.} and Keefe, {Richard S.E.} and McEvoy, {Joseph P.} and Stroup, {T. Scott} and L. Adler and M. Bari and I. Belz and R. Bland and T. Blocher and B. Bolyard and A. Buffenstein and J. Burruss and M. Byerly and J. Canive and S. Caroff and C. Casat and E. Chavez-Rice and J. Csernansky and P. Delgado and R. Douyon and C. D'Souza and I. Glick and D. Goff and S. Gratz and Grossberg, {G. T.} and M. Hale and M. Hamner and R. Jaffe and D. Jeste and S. Diego and A. Kablinger and A. Khan and S. Lamberti and Levy, {M. T.} and J. Lieberman and G. Maguire and T. Manschreck and M. McGee and H. Meltzer and A. Miller and D. Miller and H. Nasrallah and Charles Nemeroff and S. Olson and Oxenkrug, {G. F.} and J. Patel and F. Reimherr and S. Riggio and S. Risch and B. Saltz and G. Simpson and M. Smith and R. Sommi and Steinbook, {R. M.} and M. Stevens and A. Tapp and R. Torres and P. Weiden",
year = "2011",
month = "11",
day = "1",
doi = "10.1016/j.schres.2011.07.032",
language = "English (US)",
volume = "132",
pages = "177--182",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Substance use and schizophrenia

T2 - Adverse correlates in the CATIE study sample

AU - Kerfoot, Karin E.

AU - Rosenheck, Robert A.

AU - Petrakis, Ismene L.

AU - Swartz, Marvin S.

AU - Keefe, Richard S.E.

AU - McEvoy, Joseph P.

AU - Stroup, T. Scott

AU - Adler, L.

AU - Bari, M.

AU - Belz, I.

AU - Bland, R.

AU - Blocher, T.

AU - Bolyard, B.

AU - Buffenstein, A.

AU - Burruss, J.

AU - Byerly, M.

AU - Canive, J.

AU - Caroff, S.

AU - Casat, C.

AU - Chavez-Rice, E.

AU - Csernansky, J.

AU - Delgado, P.

AU - Douyon, R.

AU - D'Souza, C.

AU - Glick, I.

AU - Goff, D.

AU - Gratz, S.

AU - Grossberg, G. T.

AU - Hale, M.

AU - Hamner, M.

AU - Jaffe, R.

AU - Jeste, D.

AU - Diego, S.

AU - Kablinger, A.

AU - Khan, A.

AU - Lamberti, S.

AU - Levy, M. T.

AU - Lieberman, J.

AU - Maguire, G.

AU - Manschreck, T.

AU - McGee, M.

AU - Meltzer, H.

AU - Miller, A.

AU - Miller, D.

AU - Nasrallah, H.

AU - Nemeroff, Charles

AU - Olson, S.

AU - Oxenkrug, G. F.

AU - Patel, J.

AU - Reimherr, F.

AU - Riggio, S.

AU - Risch, S.

AU - Saltz, B.

AU - Simpson, G.

AU - Smith, M.

AU - Sommi, R.

AU - Steinbook, R. M.

AU - Stevens, M.

AU - Tapp, A.

AU - Torres, R.

AU - Weiden, P.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Objective: This study examined the relationship between severity of illicit substance use at the time of study entry in a sample of patients diagnosed with schizophrenia and 18-month longitudinal outcomes, including psychopathology, depression, neurocognition, and quality of life. Methods: Subjects in the Clinical Antipsychotic Trials of Intervention Effectiveness (N = 1432) were divided into three groups according to baseline data: (1) those with moderate/severe drug use, (2) those with mild drug use, and (3) non-users of illicit substances. The groups were compared on other baseline characteristics. Mixed model analysis was used to compare outcomes between the groups using all available outcome data over 18. months, controlling for potential confounding baseline characteristics. Least square means were compared between pairs of groups in the mixed models. Results: Significantly poorer outcomes were observed in the domains of psychosis, symptoms of depression, and quality of life for moderate/severe drug users in comparison with both mild users and abstainers. No significant differences were found on neurocognitive functioning or days of employment. Conclusions: This study suggests that drug use-related impairment co-morbid with schizophrenia may not be a function of use per se but rather, of the severity of use. It highlights the importance of comprehensive assessment and treatment of illicit substance abuse in schizophrenia. Long-term treatment approaches that integrate harm reduction strategies may offer promise in maximizing positive outcomes for such dually diagnosed patients.

AB - Objective: This study examined the relationship between severity of illicit substance use at the time of study entry in a sample of patients diagnosed with schizophrenia and 18-month longitudinal outcomes, including psychopathology, depression, neurocognition, and quality of life. Methods: Subjects in the Clinical Antipsychotic Trials of Intervention Effectiveness (N = 1432) were divided into three groups according to baseline data: (1) those with moderate/severe drug use, (2) those with mild drug use, and (3) non-users of illicit substances. The groups were compared on other baseline characteristics. Mixed model analysis was used to compare outcomes between the groups using all available outcome data over 18. months, controlling for potential confounding baseline characteristics. Least square means were compared between pairs of groups in the mixed models. Results: Significantly poorer outcomes were observed in the domains of psychosis, symptoms of depression, and quality of life for moderate/severe drug users in comparison with both mild users and abstainers. No significant differences were found on neurocognitive functioning or days of employment. Conclusions: This study suggests that drug use-related impairment co-morbid with schizophrenia may not be a function of use per se but rather, of the severity of use. It highlights the importance of comprehensive assessment and treatment of illicit substance abuse in schizophrenia. Long-term treatment approaches that integrate harm reduction strategies may offer promise in maximizing positive outcomes for such dually diagnosed patients.

KW - Concurrent

KW - Dual diagnosis

KW - Outcomes

KW - Schizophrenia

KW - Substance abuse

UR - http://www.scopus.com/inward/record.url?scp=80054073811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054073811&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2011.07.032

DO - 10.1016/j.schres.2011.07.032

M3 - Article

C2 - 21872443

AN - SCOPUS:80054073811

VL - 132

SP - 177

EP - 182

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 2-3

ER -